论文部分内容阅读
目的观察人激肽释放酶-10(human kallikrein-10,HK-10)、胰岛素样生长因子-Ⅰ(insulin-like growth factor-Ⅰ,IGF-Ⅰ)和可溶性间皮素相关蛋白(soluble mesothelin-related proteins,SM RP)在卵巢癌患者中的表达及意义。方法选择卵巢癌患者76例为卵巢癌组,同期行手术治疗卵巢良性肿瘤患者30例为卵巢良性肿瘤组,健康体检者20例健康对照组。采用ELISA法检测各组血清HK-10、IGF-Ⅰ和SMRP水平,比较卵巢癌组术前和术后,卵巢良性肿瘤组和健康对照组的血清HK-10、IGF-Ⅰ和SMRP水平;分析卵巢癌患者血清HK-10、IGF-Ⅰ和SMRP水平与临床病理指标之间的关系。结果 3组患者血清HK-10、IGF-Ⅰ和SMRP水平差异有统计学意义(F=56.157,P<0.01;F=280.021,P<0.01;F=819.326,P<0.01)。术前,卵巢癌组血清HK-10和SM RP水平较卵巢良性肿瘤组(t_1=7.054,t_2=27.939,P<0.01)和健康对照组(t_1=6.514,t_2=22.755,P<0.01)明显升高;术后,卵巢癌组血清HK-10(t=11.434,P<0.01)和SMRP(t=43.760,P<0.01)较术前明显降低,而卵巢良性肿瘤和健康对照组差异无统计学意义(P>0.05)。卵巢癌患者术前血清IGF-Ⅰ水平较卵巢良性肿瘤组(t=13.580,P<0.01)和健康对照组(t=18.592,P<0.01)明显降低,术后卵巢癌患者血清IGF-Ⅰ水平较术前明显升高(t=15.955,P<0.01),而卵巢良性肿瘤组血清IGF-Ⅰ水平明显高于健康对照组(P<0.01)。卵巢癌患者血清HK-10和SMRP水平随着肿瘤分化程度升高而降低,而IGF-Ⅰ相反(P<0.01);血清HK-10和SMRP水平随着肿瘤直径、CA125数值增大,转移程度、肿瘤分期升高而升高,而IGF-Ⅰ相反(P<0.01);血清HK-10、IGF-Ⅰ和SMRP水平不随患者年龄和病理类型改变而改变(P>0.05)。卵巢癌患者血清IGF-Ⅰ水平与HK-10(r=-0.628,P<0.05)和SMRP(r=-0.738,P<0.05)水平呈负相关,而HK-10与SM RP水平呈正相关(r=0.582,P<0.05)。结论 HK-10、IGF-Ⅰ和SM RP参与了卵巢癌的发生发展过程,对于卵巢癌的诊断和预后具有重要临床价值。
Objective To observe the effects of human kallikrein-10 (HK-10), insulin-like growth factor-Ⅰ (IGF-Ⅰ) and soluble mesothelin- related proteins, SM RP) in patients with ovarian cancer and its significance. Methods Totally 76 ovarian cancer patients were selected as ovarian cancer patients. 30 patients with ovarian benign tumor underwent surgical treatment during the same period as benign ovarian tumors and 20 healthy controls. The levels of serum HK-10, IGF-I and SMRP in each group were detected by ELISA, and the levels of serum HK-10, IGF-I and SMRP in ovarian cancer group and healthy control group were compared before and after operation Relationship between serum levels of HK-10, IGF-Ⅰ and SMRP and clinicopathological parameters in patients with ovarian cancer. Results The serum levels of HK-10, IGF-I and SMRP in the three groups were significantly different (F = 56.157, P <0.01; F = 280.021, P <0.01; F = 819.326, P <0.01). The serum levels of HK-10 and SM RP in ovarian cancer group were significantly higher than those in benign ovarian tumor group (t 1 = 7.054, t 2 = 27.939, P <0.01) and healthy control group (t 1 = 6.514, t 2 = 22.755, P <0.01) (T = 11.434, P <0.01) and SMRP (t = 43.760, P <0.01) in ovarian cancer group were significantly lower than those before operation, but there was no statistical difference between benign ovarian tumor and healthy control group Significance (P> 0.05). The level of serum IGF-Ⅰ in patients with ovarian cancer was significantly lower than that in benign ovarian tumors (t = 13.580, P <0.01) and healthy controls (t = 18.592, P <0.01) (T = 15.955, P <0.01), while the serum IGF-Ⅰ level in benign ovarian tumor group was significantly higher than that in healthy control group (P <0.01). The serum levels of HK-10 and SMRP in patients with ovarian cancer decreased with the degree of tumor differentiation, while the levels of IGF-Ⅰ were opposite (P <0.01). The levels of serum HK-10 and SMRP increased with tumor diameter, (P <0.01). The levels of serum HK-10, IGF-I and SMRP did not change with age and pathological type (P> 0.05). The level of IGF-Ⅰ in ovarian cancer patients was negatively correlated with the levels of HK-10 (r = -0.628, P <0.05) and SMRP (r = -0.738, r = 0.582, P <0.05). Conclusions HK-10, IGF-I and SM RP are involved in the development of ovarian cancer and have important clinical value for the diagnosis and prognosis of ovarian cancer.